title: Demyelinating disease associated with use of etanercept in patients with seronegative spondyloarthropathies.
authors.forename: Stacy A
authors.initials: SA
authors.lastname: Davis
authors.forename: Robert R
authors.initials: RR
authors.lastname: Johnson
authors.forename: John W
authors.initials: JW
authors.lastname: Pendleton
mesh_terms: D000328:Adult; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007155:Immunologic Factors / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D025242:Spondylarthropathies / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D016899:Interferon-beta; D000068800:Etanercept